Leonteq Securities AG’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Leonteq Securities AG’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,000	Closed	-$8.54K	–	1374
2022 Q3	$8.54K	Sell	2,000 -27,456	-93%	-$116K	﹤0.01%	1070
2022 Q2	$114K	Hold	29,456	–	–	﹤0.01%	657
2022 Q1	$140K	Sell	29,456 -3,544	-11%	-$10.7K	0.01%	659
2021 Q4	$120K	Buy	33,000 +2,500	+8%	+$13.3K	﹤0.01%	737
2021 Q3	$245K	Hold	30,500	–	–	0.01%	545
2021 Q2	$346K	Buy	30,500 +10,500	+53%	+$105K	0.02%	465
2021 Q1	$185K	Buy	+20,000	New	+$208K	0.01%	564

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Leonteq Securities AG's VIRX Position: Q4 2022 in Review

Leonteq Securities AG sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2022, closing a stake of 2,000 shares — an estimated $8.54K sold.

Leonteq Securities AG first reported a position in VIRX in Q1 2021 and held it in 7 quarters. The position peaked at $346K in Q2 2021. 56 funds tracked by Wall St. Rank hold VIRX as of Q4 2022.

Leonteq Securities AG reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Leonteq Securities AG sold 2,000 Viracta Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $8.54K.
Leonteq Securities AG first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Leonteq Securities AG's Viracta Therapeutics, Inc. Common Stock position peaked at $346K in Q2 2021.
56 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Leonteq Securities AG's 13F filing for Q4 2022, filed 26 Mar 2026.